Clinical Trial Search

Primary: Hemoglobin A1C at 4 Weeks — 10.5; 11.1 percentage of glycosylated hemoglobin

Primary: Hyperglycaemia Avoidance Scale — 44.6 score on a scale

Primary: Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit — 0 events

Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35

Primary: Mean POC Glucose Level Between Groups — 225; 266 mg/dl

Primary: Type 2 Diabetes Blood Glucose Time in Range (70-180 mg/dL) — 25.31; 19.89; 26.04 percentage of time during CGM use — p=0.1460

Primary: Hospital Length of Stay — 7; 8 days

Primary: Number of Participants Who Experienced a Primary Combined Outcome — 174; 181 participants — p=0.866

Primary: Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours — 13.0; 22.5 hours

Primary: Glycemic Response During Exercise and Early Recovery — 86; 85; 174; 161 mg/dL — p=<0.001

Primary: Time to Achieve Glycemic Control — 225 Minutes

Primary: Change in Mean Glucose (mg/dL) From Baseline — 2.1 mg/dL — p=0.8

Primary: Prevalence of Hyperglycemia in the Elective Orthopedic Population — 140 patients

Primary: Mean Blood Glucose of All Readings — 157.2; 181.8 mg/dL

Primary: Mean Fasting Blood Glucose — 162; 157 mg/dL

Primary: Glycemic Control — 10.7; 10.9 mmol/L — p=0.677

Primary: Time in Target Blood Glucose Range (BG 70-180mg/dL) — 60.5; 61.4 percentage of time within target range

Primary: Self-reported Severe Hypoglycemia — 99; 99; 19; 13 Participants — p=0.27

Primary: Differences in Glycemic Control as Measured by Time Reach Glycemic Control for Each Treatment Group. — 5; 10.1; 7.7 Time to reach glycemic control in hours — p=<0.05

Primary: Change in Diabetes Distress — 0; 0.5 units on a scale

Primary: Hypoglycemic Events — 0.27; 1.0; 0.18; 0.18 events/patient

Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67

Primary: Percentage of Time Spent in Hyperglycemia > 180 mg/dL — 35.47; 35.25 percentage of time spent > 180mg/dL

Primary: Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment — 17.31; 17.53; 15.30; 10.83 Hours — p=0.064

Primary: Hospital Length of Stay — 7; 8 days

Primary: Measure of Biochemical Parameters and Evaluation of Infectious Complications 1 — 138.6; 146.1; 143.9; 146.1 mg/dL

Primary: Glucose Time in Range — 495.2; 573.3 minutes per day

Primary: CT Abdomen — 0.08; -0.03 ratio

Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants

Primary: Mortality — 36 mortality rate